ArticleMediators of inflammation2014
5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.
Article in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Hypomethylating agents are the current therapy backbone for MDS and AML relapsing after allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2026Review
- The epigenetic hallmarks of immune cells in cancer.Molecular cancer · 2025Review
- Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation.Nature immunology · 2024Article
- Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.Frontiers in immunology · 2024Review
- Targeting the epigenome to reinvigorate T cells for cancer immunotherapy.Military Medical Research · 2023Review
- Hypomethylation-induced regulatory programs in T cells unveiled by transcriptomic analyses.Frontiers in immunology · 2023Article
- Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia.Frontiers in immunology · 2023Article
- Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT.Bone marrow transplantation · 2022Review
- Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.Frontiers in immunology · 2022Review
- Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.Nature communications · 2021Article
- Reactivation of Pulmonary Tuberculosis During Treatment of Chronic Myelomonocytic Leukemia.Cureus · 2021Article
- Pharmacological modulation of T cell immunity results in long-term remission of autoimmune arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations.Frontiers in immunology · 2021Review
- Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.Frontiers in immunology · 2021Review
- Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism.Frontiers in oncology · 2021Review
- Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.Cancer immunology, immunotherapy : CII · 2020Review
- Targeting the epigenetic regulation of antitumour immunity.Nature reviews. Drug discovery · 2020Review
- High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications.Frontiers in immunology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Demethylating agent, 5-Azacytidine (5-Aza), has been shown to be active in treatment of myeloid malignancies. 5-Aza enhances anticancer immunity, by increasing expression of tumor-associated antigens. However, the impact of 5-Aza immune responses remains poorly understood. Here, T-cell mediated tumor immunity effects of 5-Aza, are investigated in vitro and in vivo. T-cells from healthy donors were treated with 5-Aza and analyzed by qRT-PCR and flow cytometry for changes in gene expression and phenotype. Functionality was assessed by a tumor lysis assay. Peripheral blood from patients treated with 5-Aza after alloSCT was monitored for changes in T-cell subpopulations. 5-Aza treatment resulted in a decrease in CD8+ T-cells, whereas CD4+ T-cells increased. Furthermore, numbers of IFN-γ + T-helper 1 cells (Th1) were reduced, while Treg-cells showed substantial increase. Additionally, CD8+ T-cells exhibited limited killing capacity against leukemic target cells. In vivo data confirm the increase of Treg compartment, while CD8+ T-effector cell numbers were reduced. 5-Aza treatment results in a shift from cytotoxic to regulatory T-cells with a functional phenotype and a major reduction in proinflammatory Th1-cells, indicating a strong inhibition of tumor-specific T-cell immunity by 5-Aza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.